Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.

Abstract: An electrical device that includes an electrically-conductive substrate having a flexible structure; and wherein the flexible structure is formed by coating, encapsulating, and entangling it with porous silicon nano-particles, and wherein the porous silicon nano-particles are produced according to steps of: (I) alloying a raw silicon material with at least one distillable alloying metal selected from zinc and magnesium to form an alloy; (II) milling the alloy to form alloy nano-particles of 100 nm-150 nm in diameter, and doing the milling in an inert environment to alleviate oxidation of the alloy; (III) distilling the alloying metal from the alloy nano-particles so that a porous silicon structure is produced, the distilling being performed in a vacuum furnace; and (IV) milling the porous silicon structure in an inert environment to break the porous silicon structure apart, thereby to produce the porous silicon nano-particles.

Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

Abstract: Various embodiments provide an optical lens that includes wafer level diffractive microstructures. In one embodiment, the optical lens includes a substrate, a microstructure layer having a first refractive index, and a protective layer having a second refractive index that is different from the first refractive index. The microstructure layer is formed on the substrate and includes a plurality of diffractive microstructures. The protective layer is formed on the diffractive microstructures. The protective layer provides a cleanable surface and encapsulates the diffractive microstructures to prevent damage and contamination to the diffractive microstructures. In another embodiment, the optical lens includes a substrate and an anti-reflective layer. The anti-reflective layer is formed on the substrate and includes a plurality of diffractive microstructures.

Abstract: Disclosed herein are novel processes for the production of oligonucleotides that are suitable for use in the production of chemically modified oligonucleotides, such as those for use in therapy.

Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.

Abstract: In accordance with an embodiment, a system includes: a primary device configured to be connected to at least one secondary device via serial bus having a data wire and a clock wire. The primary device is configured to: provide a clock signal on the clock wire; and transmit a frame comprising control bits on the serial bus, wherein a number of control bits transmitted on the serial bus at at least one location of the frame indicates a format of the frame.

Abstract: Compounds of formula (1) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (1), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions.

Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.

Abstract: Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (F AAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.

Abstract: In some implementations, a device may receive an image that depicts an environment associated with a vehicle. The device may partition the image into a plurality of subsections. The device may analyze the plurality of subsections to determine respective subsection information, wherein subsection information, for an individual subsection, indicates: a probability score that the subsection includes a line segment associated with an object class, a position of a representative point of the line segment, and a direction of the line segment. The device may identify, based on the respective subsection information of the plurality of subsections, a line associated with the object class that is associated with a set of subsections of the plurality of subsections. The device may perform one or more actions based on identifying the line associated with the object class.

Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.

Abstract: The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.

Abstract: An imaging device includes a sensor array with a number of pixels. In an embodiment, the imaging device can be operated by capturing a first low-spatial resolution frame using a subset of pixels of the sensor array and then capturing a second low-spatial resolution frame using the same subset of pixels of the sensor array. A first depth map is generated using raw pixel values of the first low-spatial resolution frame and a second depth map is generated using raw pixel values of the second low-spatial resolution frame. The first depth map can be compared to the second depth map to determine whether an object has moved in a field of view of the imaging device.

Abstract: The present invention relates to a method of producing a composite rod from a braze material and a sheet of material comprising cermet. The method comprises scoring a surface of the sheet to produce at least one line of localised stress and subsequently causing the sheet to break along the line or localised stress, thereby to produce a plurality of cermet chunks. The cermet chunks can be combined with the braze material to produce the composite rod. In a particular embodiment, the sheet of material may be a used cermet cutting tip.

Abstract: A new distinct variety of grapevine named ‘ARD47’ abundantly forms attractive crunchy seedless berries with a yellow-green skin coloration of medium density and large clusters which display a labrusca flavor, and is commonly ready for harvesting during July-August in San Joaquin Valley of Central California, U.S.A, and displays good eating qualities as a table grape, the fruit firmness renders the fruit well amenable for handling, shipping, and storage.

Abstract: A new distinct variety of grapevine named ‘ARD51’ abundantly forms attractive crunchy and juicy seedless berries with a red skin coloration, lax density and large clusters which display a natural sweet flavor, the fruit commonly is ready for harvesting during July in San Joaquin Valley of Central California, U.S.A., and displays good eating qualities as a table grape, the fruit firmness renders the fruit well amenable for handling, shipping, and storage.

Abstract: A new distinct variety of grapevine named ‘ARD49’ abundantly forms attractive crunchy and juicy seedless berries with a yellow-green skin coloration, dense and large sized clusters which display a muscat flavor, the fruit is commonly ready for harvesting during June-July in San Joaquin Valley of Central California, U.S.A., and displays good eating qualities as a table grape, the fruit firmness renders the fruit well amenable for handling, shipping, and storage.